Healthcare >> CEO Interviews >> May 27, 2003

Daniel Glassman – Bradley Pharmaceuticals Inc (bdy)

DANIEL GLASSMAN is Chairman of the Board, President and Chief Executive Officer of Bradley Pharmaceuticals, Inc., which he founded in 1985. Mr. Glassman was the key force that took the company public as a NASDAQ traded corporation in November 1991 and drove the transition to the New York Stock Exchange on May 13, 2003. Mr. Glassman also is Chairman of the Board and Chief Executive Officer of Doak Dermatologics, Bradley Pharmaceuticals Ltd., each a subsidiary of Bradley Pharmaceuticals, Inc. Mr. Glassman has 32 years experience in pharmaceutical management and healthcare communications. He is actively involved in the development of medical education programs for numerous pharmaceutical and medical professional associations. Mr. Glassman is an associate member of the American Academy of Dermatology as well as a lecturer, publisher and author. He has been named the Ernst & Young LLP Entrepreneur of the Year (1995) in the New Jersey Life Sciences division. Mr. Glassman pursued his undergraduate degree at Columbia University, where he served as Class President from 1960-1962 and Student Council President from 1962-1963. He received his BS in Pharmacy, and went on to achieve an MBA from New York University. Mr. Glassman serves as a member of the University Advisory Committee, Long Island University Health Sciences and has authored a chapter entitled 'The History of the FDA Communications Regulations' in a soon-to-be- published book. Profile
TWST: Could you give us a brief overview of Bradley


Mr. Glassman: Bradley Pharmaceuticals was founded in 1985 as a

specialty pharmaceutical company that markets to niche